SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Unitedhealth Group Inc – ‘10-K’ for 12/31/17 – ‘R24’

On:  Tuesday, 2/13/18, at 4:10pm ET   ·   For:  12/31/17   ·   Accession #:  731766-18-5   ·   File #:  1-10864

Previous ‘10-K’:  ‘10-K’ on 2/8/17 for 12/31/16   ·   Next:  ‘10-K’ on 2/12/19 for 12/31/18   ·   Latest:  ‘10-K’ on 2/28/24 for 12/31/23   ·   2 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/13/18  Unitedhealth Group Inc            10-K       12/31/17  103:18M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.36M 
 2: EX-10.51    Material Contract                                   HTML     68K 
 4: EX-21.1     Subsidiaries List                                   HTML    229K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     30K 
 6: EX-24.1     Power of Attorney                                   HTML     38K 
 3: EX-12.1     Statement re: Computation of Ratios                 HTML     42K 
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     44K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     33K 
15: R1          Document and Entity Information Document            HTML     58K 
16: R2          Consolidated Balance Sheets                         HTML    125K 
17: R3          Consolidated Balance Sheet (Parenthetical)          HTML     55K 
18: R4          Consolidated Statements of Operations               HTML     97K 
19: R5          Consolidated Statements of Comprehensive Income     HTML     66K 
20: R6          Consolidated Statements of Changes in Equity        HTML    109K 
21: R7          Consolidated Statements of Cash Flows               HTML    124K 
22: R8          Description of Business (Notes)                     HTML     30K 
23: R9          Basis of Presentation, Uses of Estimates and        HTML     95K 
                Significant Accounting Policies (Notes)                          
24: R10         Investments (Notes)                                 HTML    252K 
25: R11         Fair Value (Notes)                                  HTML    180K 
26: R12         Property, Plant, and Capitalized Software (Notes)   HTML     52K 
27: R13         Goodwill and Intangible Assets (Notes)              HTML    115K 
28: R14         Medical Costs Payable (Notes)                       HTML     79K 
29: R15         Commercial Paper and Long-Term Debt (Notes)         HTML    237K 
30: R16         Income Taxes (Notes)                                HTML    159K 
31: R17         Shareholders' Equity (Notes)                        HTML     49K 
32: R18         Share-Based Compensation (Notes)                    HTML    110K 
33: R19         Commitments and Contingencies (Notes)               HTML     48K 
34: R20         Segment Financial Information (Notes)               HTML    306K 
35: R21         Quarterly Financial Data (Unaudited) (Notes)        HTML     80K 
36: R22         Schedule I (Notes)                                  HTML    200K 
37: R23         Basis of Presentation, Uses of Estimates and        HTML    153K 
                Significant Accounting Policies (Policies)                       
38: R24         Fair Value Fair Value (Policies)                    HTML     43K 
39: R25         Schedule I (Policies)                               HTML    121K 
40: R26         Basis of Presentation, Uses of Estimates and        HTML     69K 
                Significant Accounting Policies (Tables)                         
41: R27         Investments (Tables)                                HTML    250K 
42: R28         Fair Value (Tables)                                 HTML    170K 
43: R29         Property, Plant, and Capitalized Software (Tables)  HTML     50K 
44: R30         Goodwill and Intangible Assets (Tables)             HTML    120K 
45: R31         Medical Costs Payable (Tables)                      HTML     80K 
46: R32         Commercial Paper and Long-Term Debt (Tables)        HTML    236K 
47: R33         Income Taxes (Tables)                               HTML    160K 
48: R34         Shareholders' Equity (Tables)                       HTML     41K 
49: R35         Share-Based Compensation (Tables)                   HTML    113K 
50: R36         Commitments and Contingencies (Tables)              HTML     39K 
51: R37         Segment Financial Information (Tables)              HTML    297K 
52: R38         Quarterly Financial Data (Unaudited) (Tables)       HTML     80K 
53: R39         Schedule I (Tables)                                 HTML    204K 
54: R40         Basis of Presentation, Uses of Estimates and        HTML     86K 
                Significant Accounting Policies (Details)                        
55: R41         Basis of Presentation, Uses of Estimates and        HTML     41K 
                Significant Accounting Policies Useful lives for                 
                property, equipment and capitalized software                     
                (Details)                                                        
56: R42         Basis of Presentation, Uses of Estimates and        HTML     52K 
                Significant Accounting Policies Redeemable                       
                Noncontrolling Interests (Details)                               
57: R43         Investments (Narrative) (Details)                   HTML     36K 
58: R44         Investments (Short-Term and Long-Term Investments)  HTML     95K 
                (Details)                                                        
59: R45         Investments (Amortized Cost and Fair Value of       HTML    103K 
                Available-for-Sale Debt Securities by Contractual                
                Maturity) (Details)                                              
60: R46         Investments (Fair Value of Available-For-Sale       HTML     73K 
                Investments with Gross Unrealized Losses by                      
                Investment Type and Length of Time That Individual               
                Securities Have Been in a Continuous Unrealized                  
                Loss Position) (Details)                                         
61: R47         Investments (Net Realized Gains) (Details)          HTML     48K 
62: R48         Fair Value (Narrative) (Details)                    HTML     46K 
63: R49         Fair Value (Financial Assets and Liabilities,       HTML     88K 
                Measured at Fair Value on a Recurring Basis)                     
                (Details)                                                        
64: R50         Fair Value (Financial Assets and Liabilities, Not   HTML     78K 
                Measured at Fair Value on a Recurring Basis)                     
                (Details)                                                        
65: R51         Property, Plant, and Capitalized Software           HTML     34K 
                (Details)                                                        
66: R52         Property, Plant, and Capitalized Software Property  HTML     53K 
                Plant and Equipment Table (Details)                              
67: R53         Goodwill and Intangible Assets (Details)            HTML     32K 
68: R54         Goodwill and Intangible Assets Changes in the       HTML     49K 
                Carrying Amount of Goodwill by Reporting Segment                 
                (Details)                                                        
69: R55         Goodwill and Intangible Assets Gross carrying       HTML     47K 
                value, accumulated amortization and net carrying                 
                value of intangible assets (Details)                             
70: R56         Goodwill and Intangible Assets Weighted-average     HTML     41K 
                useful lives assigned to finite-lived intangible                 
                assets acquired in business combinations (Details)               
71: R57         Goodwill and Intangible Assets Amortization         HTML     40K 
                Expense relating to Intangible Assets (Details)                  
72: R58         Medical Costs Payable (Details)                     HTML     29K 
73: R59         Medical Costs Payable Rollforward (Details)         HTML     53K 
74: R60         Medical Costs Payable, Incurred and Paid Medical    HTML     43K 
                Cost Development (Details)                                       
75: R61         Commercial Paper and Long-Term Debt (Narrative)     HTML     65K 
                (Details)                                                        
76: R62         Commercial Paper and Long-Term Debt (Details)       HTML    191K 
77: R63         Commercial Paper and Long-Term Debt Maturities of   HTML     45K 
                commercial paper and long-term debt (Details)                    
78: R64         Income Taxes (Details)                              HTML     62K 
79: R65         Income Taxes Reconciliation of Provision for        HTML     46K 
                Income Taxes (Details)                                           
80: R66         Income Tax Reconciliation of the tax provision at   HTML     80K 
                the U.S. Federal Statutory Rate (Details)                        
81: R67         Income Taxes Components of Deferred Tax Assets and  HTML     79K 
                Liabilities (Details)                                            
82: R68         Income Taxes Reconciliation of the beginning and    HTML     45K 
                ending amount of unrecognized tax benefits                       
                (Details)                                                        
83: R69         Shareholders' Equity (Details)                      HTML     45K 
84: R70         Shareholders' Equity Share Repurchases (Details)    HTML     40K 
85: R71         Share-Based Compensation Narrative (Details)        HTML     36K 
86: R72         Share-Based Compensation (Stock Option and SAR      HTML     76K 
                Activity) (Details)                                              
87: R73         Share-Based Compensation (Restricted Share          HTML     46K 
                Activity) (Details)                                              
88: R74         Share-Based Compensation Other Share-Based          HTML     61K 
                Compensation Data (Details)                                      
89: R75         Share-Based Compensation (Share-Based Compensation  HTML     48K 
                Principal Fair Value Assumptions) (Details)                      
90: R76         Commitments and Contingencies (Details)             HTML     36K 
91: R77         Commitments and Contingencies Future Lease          HTML     45K 
                Payments (Details)                                               
92: R78         Segment Financial Information (Narrative)           HTML     43K 
                (Details)                                                        
93: R79         Segment Financial Information (Details)             HTML    121K 
94: R80         Quarterly Financial Data (Unaudited) (Details)      HTML     61K 
95: R81         Schedule I (Details)                                HTML     41K 
96: R82         Schedule I Condensed Balance Sheets (Details)       HTML    109K 
97: R83         Schedule I Balance Sheet Document (Details)         HTML     49K 
98: R84         Schedule I Condensed Statement of Comprehensive     HTML     66K 
                Income (Details)                                                 
99: R85         Schedule I Statement of Cash Flows (Details)        HTML    102K 
100: R86         Schedule I Maturities of Commercial Paper and       HTML     48K  
                Long-Term Debt (Details)                                         
102: XML         IDEA XML File -- Filing Summary                      XML    190K  
101: EXCEL       IDEA Workbook of Financial Reports                  XLSX    133K  
 9: EX-101.INS  XBRL Instance -- unh-20171231                        XML   5.79M 
11: EX-101.CAL  XBRL Calculations -- unh-20171231_cal                XML    313K 
12: EX-101.DEF  XBRL Definitions -- unh-20171231_def                 XML   1.44M 
13: EX-101.LAB  XBRL Labels -- unh-20171231_lab                      XML   2.38M 
14: EX-101.PRE  XBRL Presentations -- unh-20171231_pre               XML   1.66M 
10: EX-101.SCH  XBRL Schema -- unh-20171231                          XSD    219K 
103: ZIP         XBRL Zipped Folder -- 0000731766-18-000005-xbrl      Zip    409K  


‘R24’   —   Fair Value Fair Value (Policies)


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.8.0.1
Fair Value Fair Value (Policies)
12 Months Ended
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Fair Value Measurement, Policy [Policy Text Block]
Certain assets and liabilities are measured at fair value in the Consolidated Financial Statements or have fair values disclosed in the Notes to the Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement is categorized in its entirety based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.
The fair value hierarchy is summarized as follows:
Level 1 — Quoted prices (unadjusted) for identical assets/liabilities in active markets.
Level 2 — Other observable inputs, either directly or indirectly, including:
Quoted prices for similar assets/liabilities in active markets;
Quoted prices for identical or similar assets/liabilities in inactive markets (e.g., few transactions, limited information, noncurrent prices, high variability over time);
Inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves, implied volatilities, credit spreads); and
Inputs that are corroborated by other observable market data.
Level 3 — Unobservable inputs that cannot be corroborated by observable market data.
Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs; there was no transfer between Levels 1, 2 or 3 of any financial assets or liabilities during the year ended December 31, 2017 or 2016.
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during the year ended December 31, 2017 or 2016.
The following methods and assumptions were used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument included in the tables below:
Cash and Cash Equivalents. The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. Fair values of cash equivalent instruments that do not trade on a regular basis in active markets are classified as Level 2.
Debt and Equity Securities. Fair values of debt and equity securities are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service (pricing service), which generally uses quoted or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, and, if necessary, makes adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment speeds and nonbinding broker quotes. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to prices reported by a secondary pricing source, such as its custodian, its investment consultant and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company’s internal price verification procedures and reviews of fair value methodology documentation provided by independent pricing services have not historically resulted in adjustment in the prices obtained from the pricing service.
Fair values of debt securities that do not trade on a regular basis in active markets but are priced using other observable inputs are classified as Level 2.
Fair value estimates for Level 1 and Level 2 equity securities are based on quoted market prices for actively traded equity securities and/or other market data for the same or comparable instruments and transactions in establishing the prices.
The fair values of Level 3 investments in venture capital portfolios are estimated using a market valuation technique that relies heavily on management assumptions and qualitative observations. Under the market approach, the fair values of the Company’s various venture capital investments are computed using limited quantitative and qualitative observations of activity for similar companies in the current market. The Company’s market modeling utilizes, as applicable, transactions for comparable companies in similar industries that also have similar revenue and growth characteristics and preferences in their capital structure. Key significant unobservable inputs in the market technique include implied earnings before interest, taxes, depreciation and amortization (EBITDA) multiples and revenue multiples. Additionally, the fair values of certain of the Company’s venture capital securities are based on recent transactions in inactive markets for identical or similar securities. Significant changes in any of these inputs could result in significantly lower or higher fair value measurements.
Throughout the procedures discussed above in relation to the Company’s processes for validating third-party pricing information, the Company validates the understanding of assumptions and inputs used in security pricing and determines the proper classification in the hierarchy based on that understanding.
Assets Under Management. Assets under management consists of debt securities and other investments held to fund costs associated with the AARP Program and are priced and classified using the same methodologies as the Company’s investments in debt and equity securities.
Long-Term Debt. The fair values of the Company’s long-term debt are estimated and classified using the same methodologies as the Company’s investments in debt securities.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/13/183,  4,  8-K,  SC 13G/A
For Period end:12/31/1711-K
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/11/18  SEC                               UPLOAD5/09/18    1:38K  UnitedHealth Group Inc.
 3/22/18  SEC                               UPLOAD5/09/18    1:47K  UnitedHealth Group Inc.
Top
Filing Submission 0000731766-18-000005   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 10, 12:26:02.1am ET